Keywords: ریواروکسابان; anticoagulation; apixaban; cutaneous surgery; dabigatran; novel drugs; rivaroxaban; warfarinCYP3A4, cytochrome P450 3A4; NOAC, novel oral anticoagulant; P-gp, permeability glycoprotein
مقالات ISI ریواروکسابان (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ریواروکسابان; Hemodialysis; rivaroxaban; anticoagulant; anti-FXa activity; atrial fibrillation; stroke; end-stage renal disease (ESRD); area under the curve (AUC); pharmacokinetics; pharmacodynamics; dose finding; dose adjustment; dosing guideline;
Keywords: ریواروکسابان; Bleeding; New oral anticoagulants; Rivaroxaban; Dabigatran; Apixaban; Meta-analysis;
Keywords: ریواروکسابان; anticoagulant; antiplatelet; apixaban; blood thinners; dabigatran; dermatologic surgery; dietary supplements; prasugrel; rivaroxaban; ticagrelorADP, adenosine diphosphate; AF, atrial fibrillation; CVA, cerebrovascular accident; FDA, Food and Drug Administ
Keywords: ریواروکسابان; Anciano; Fibrilación auricular no valvular; Guías; Antagonistas de la vitamina K; Dabigatran; Rivaroxaban; Apixaban; EdoxabanElderly; Nonvalvular atrial fibrillation; Guidelines; Vitamin K antagonists; Dabigatran; Rivaroxaban; Apixaban; Edoxaban
Keywords: ریواروکسابان; Elderly; Nonvalvular atrial fibrillation; Guidelines; Vitamin K antagonists; Dabigatran; Rivaroxaban; Apixaban; EdoxabanAnciano; Fibrilación auricular no valvular; Guías; Antagonistas de la vitamina K; Dabigatran; Rivaroxaban; Apixaban; Edoxaban
Keywords: ریواروکسابان; Novel oral anticoagulants; Apixaban; Dabigatran; Edoxaban; Rivaroxaban; Cost-effectiveness; Atrial fibrillationNovos anticoagulantes orais; Apixabano; Dabigatrano; Edoxabano; Rivaroxabano; Custo-efetividade; Fibrilhação auricular
Keywords: ریواروکسابان; anticoagulation; apixaban; atrial fibrillation; cost-effectiveness; dabigatran; rivaroxaban;
Keywords: ریواروکسابان; AF; SPAF; Dabigatran; Rivaroxaban; Apixaban;
Keywords: ریواروکسابان; Atrial fibrillation; Stroke; Dabigatran; Rivaroxaban; Thrombolysis
Keywords: ریواروکسابان; Aspirin; Apixaban; Dabigatran; Edoxaban; Rivaroxaban; Oral anticoagulants; Pulmonary embolism; Venous thromboembolism; Venous thrombosis
Keywords: ریواروکسابان; Acenocoumarol (PubChem CID: 54676537); Bemiparin (PubChem CID: 25244225); Dabigatran (PubChem CID: 216210); Enoxaparin (PubChem CID: 772); Fondaparinux (PubChem CID: 5282448); Heparin (PubChem CID: 444410); Idraparinux (PubChem CID: 3083445); Rivaroxaban
Keywords: ریواروکسابان; Venous thromboembolism; Extended treatment; Anticoagulation; Rivaroxaban; Cost-effectiveness analysis; Markov model;
Keywords: ریواروکسابان; Venous thromboembolism; Cancer; New oral anticoagulants; Apixaban; Dabigatran; Rivaroxaban; Edoxaban
Keywords: ریواروکسابان; anticoagulation; apixaban; dabigatran etexilate; deep vein thrombosis; rivaroxaban; venous thromboembolism
Keywords: ریواروکسابان; Venous thromboembolism; Dabigatran; Rivaroxaban; Apixaban; Edoxaban; Warfarin;
Keywords: ریواروکسابان; Bleeding; Safety; Dabigatran; Rivaroxaban; Apixaban; Prothrombin complex concentrates;
Keywords: ریواروکسابان; Atrial fibrillation; Cost-effectiveness; Portugal; Rivaroxaban; StrokeFibrilhação Auricular; Custo-efetividade; Portugal; Rivaroxabano; AVC
Keywords: ریواروکسابان; Dabigatran; Apixaban; Rivaroxaban; Traveller's thrombosis; Anticoagulation
Keywords: ریواروکسابان; Atrial fibrillation; Stroke; Dabigatran; Rivaroxaban; Apixaban; Edoxaban;
Keywords: ریواروکسابان; apixaban; bleeding; dabigatran; direct oral anticoagulant; edoxaban; management; pharmacology; rivaroxaban; ACS; acute coronary syndrome; AF; atrial fibrillation; ASA; acetylsalicylic acid; bid; twice daily; CrCl; creatinine clearance; CYP; cytochrome P45
Keywords: ریواروکسابان; Deep vein; Thrombosis; Pulmonary embolism; Rivaroxaban; Warfarin;
Keywords: ریواروکسابان; Dabigatran; Rivaroxaban; Apixaban;
Keywords: ریواروکسابان; anticoagulant; dabigatran; rivaroxaban; bleeding; antidote;
Keywords: ریواروکسابان; ADP receptor antagonists; dabigatran; fondaparinux; glycoprotein IIb/IIIa antagonists; heparin; rivaroxaban; warfarin
Commentary concerning the “Measurement and correlation of the solubility of rivaroxaban (form I) in binary mixtures of ethyl acetate with tetrahydrofuran, N,N-dimethylformamide, and N,N-dimethylacetamide from Tâ¯=â¯(278.15 to 318.15)â¯K”
Keywords: ریواروکسابان; Rivaroxaban; Solubility; N,N-dimethylformamide; Ethyl acetate; Jouyban-Acree model; λh equation;
Improvement of distal acquired demyelinating symmetric (DADS) neuropathy after exposure to factor Xa inhibitor
Keywords: ریواروکسابان; DADS neuropathy; Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP); Factor Xa inhibitor; Rivaroxaban; Demyelinating neuropathy;
Ischemia and Bleeding on the Horns of a Dilemma
Keywords: ریواروکسابان; bleeding; hard endpoints; ischemia; rivaroxaban;
Ãpistaxis compliquant un traitement par anti-vitamine K et nouveaux anticoagulants oraux
Keywords: ریواروکسابان; Ãpistaxis; Rivaroxaban; Dabigatran; Anticoagulants oraux;
Epistaxis complicating treatment by anti-vitamin K and new oral anticoagulants
Keywords: ریواروکسابان; Epistaxis; Rivaroxaban; Dabigatran; Oral anticoagulants;
A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2)
Keywords: ریواروکسابان; Central venous catheters; Deep vein thrombosis; Neoplasms; Rivaroxaban; Upper extremity deep vein thrombosis;
Point of Care Testing (POCT) to assess drug concentration in patients treated with non-vitamin K antagonist oral anticoagulants (NOACs)
Keywords: ریواروکسابان; Apixaban; Concentration; Dabigatran; Emergency; Point of Care Test; Rivaroxaban;
Efficacy and safety of rivaroxaban in extreme elderly patients with atrial fibrillation: Analysis of the Shikoku Rivaroxaban Registry Trial (SRRT)
Keywords: ریواروکسابان; Rivaroxaban; Anticoagulants; Extreme elderly; Atrial fibrillation;
Use of DOAC Stop for elimination of anticoagulants in the thrombin generation assay
Keywords: ریواروکسابان; Thrombin generation assay; Direct oral anticoagulants; DOAC adsorbent; Dabigatran; Rivaroxaban; Edoxaban; Apixaban;
Sub therapeutic rivaroxaban plasma concentrations following administration via Percutaneous Endoscopic Gastrostomy (PEG) feeding tubes - A note of caution
Keywords: ریواروکسابان; Absorption; Apixaban; Feeding tubes; Rivaroxaban; Stroke;
Simple method for removing DOACs from plasma samples
Keywords: ریواروکسابان; DOAC; Dabigatran; Apixaban; Rivaroxaban; Edoxaban; APTT; dRVVT; Lupus anticoagulant; Clotting tests; DOAC adsorbent;
Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state
Keywords: ریواروکسابان; Rivaroxaban; Venous thromboembolism; Primary hypercoagulable states;
Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome
Keywords: ریواروکسابان; Deep vein thrombosis; Post-thrombotic syndrome; Quality of life; Rivaroxaban; Warfarin;
An analysis on distribution and inter-relationships of biomarkers under rivaroxaban in Japanese patients with non-valvular atrial fibrillation (CVI ARO 1)
Keywords: ریواروکسابان; Rivaroxaban; Atrial fibrillation; Anticoagulation; Prothrombin time; Serum concentration; Population pharmacokinetics;
Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF
Keywords: ریواروکسابان; Rivaroxaban; Atrial fibrillation; Net clinical benefit;
Venous thromboembolism therapy with rivaroxaban in daily-care patients: Results from the Dresden NOAC registry
Keywords: ریواروکسابان; Anticoagulation; Bleeding; Persistence; Rivaroxaban; Venous thromboembolism;
The safety and efficacy of non-vitamin K antagonist oral anticoagulants in atrial fibrillation in the elderly
Keywords: ریواروکسابان; Apixaban; Atrial fibrillation; Dabigatran; Non-vitamin K antagonist oral anticoagulant; Edoxaban; Rivaroxaban;
Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome
Keywords: ریواروکسابان; acute coronary syndrome; factor Xa inhibitor; net clinical outcome; risk-benefit; rivaroxaban; ACS; acute coronary syndrome; CV; cardiovascular; ICH; intracranial hemorrhage; MI; myocardial infarction; TIMI; Thrombolysis In Myocardial Infarction;
Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke
Keywords: ریواروکسابان; Stroke volume; recurrent; NOAC; DOAC; direct thrombin inhibitor; dabigatran; factor Xa inhibitor; rivaroxaban; apixaban; edoxaban; warfarin;
What have we learned from real-world NOAC studies in venous thromboembolism treatment?
Keywords: ریواروکسابان; Real world evidence; Apixaban; Dabigatran; Edoxaban; Rivaroxaban; Venous thromboembolism;
Bleeding in advanced CKD patients on antithrombotic medication - A critical appraisal
Keywords: ریواروکسابان; acetylsalicylic acid; clopidogrel; prasugrel; ticagrelor; dabigatran; rivaroxaban; apixaban; warfarin; heparin; low molecular weight heparin; proton pump inhibitors; Bleeding; Chronic kidney disease; Management; Risk;
Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial
Keywords: ریواروکسابان; Stroke; cryptogenic stroke; cerebral embolism; Embolic Stroke of Undetermined Source (ESUS); stroke prevention; rivaroxaban; aspirin; randomized trial;
Measurement of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma using automated online solid-phase extraction combined with ultra-performance liquid chromatography-tandem mass spectrometry and its comparison with coagulation assays
Keywords: ریواروکسابان; aPTT; activated partial thromboplastin time; BEH; bridged ethyl hybrid; CV; coefficient of variation; DOACs; direct oral anticoagulants; DTI; direct thrombin inhibitor(s); IS; internal standard; MRM; multiple reaction monitoring mode; MS/MS; tandem mass s
Global Prospective Safety Analysis of Rivaroxaban
Keywords: ریواروکسابان; atrial fibrillation; real-world; rivaroxaban; safety; stroke prevention; XANTUS; AE; adverse event; AF; atrial fibrillation; CNS; central nervous system; CrCl; creatinine clearance; DOAC; direct oral anticoagulant; ICH; intracranial hemorrhage; ISTH; Inte
Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism
Keywords: ریواروکسابان; Anticoagulants; Frailty; Rivaroxaban; Venous thromboembolism; Warfarin;